SCL Science Inc. (KOSDAQ:246960)

Market Cap	61.53B -10.6%
Revenue (ttm)	27.40B +366.8%
Net Income	-3.17B
EPS	-92.99
Shares Out	34.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,695
Open	1,895.00
Previous Close	1,869.00
Day's Range	1,750.00 - 1,900.00
52-Week Range	1,612.00 - 5,110.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2025, SCL Science's revenue was 22.01 billion, an increase of 364.64% compared to the previous year's 4.74 billion. Losses were -3.93 billion, 5.47% more than in 2024.